Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.49) by 10.2 percent. This is unchanged from the same period last year. The company reported quarterly sales of $380.00 thousand which beat the analyst consensus estimate of $200.00 thousand by 90.00 percent. This is the same as the same period last year.